Search Results

You are looking at 1 - 10 of 129 items for :

  • "autologous stem cell transplantation" x
Clear All
Full access

Leona Holmberg and David G. Maloney

address these issues, and most studies have not included functional imaging. In addition, no unified acceptance of prognostic HL risk factors exists for comparing outcomes. Table 1 Results of Autologous Stem Cell Transplant in Hodgkin Lymphoma

Full access

Ashraf Badros

with neutral or somewhat favorable prognosis. 8 , 9 Deletion of chromosome 17p13, present in 10% of patients, confers poorer survival. Patients with this deletion who undergo HDT followed by autologous stem cell transplantation (ASCT) have

Full access

Michael D. DeVita, Andrew M. Evens, Steven T. Rosen, Paul A. Greenberger and Adam M. Petrich

to high-dose chemotherapy and autologous stem cell transplant (HDT-ASCT) at that time. She underwent consolidative radiation, during which she developed a scalp nodule and cervical lymphadenopathy, biopsy of which confirmed disease recurrence. She

Full access

Jean-Luc Harousseau

Edited by Kerrin G. Robinson

-term survival of younger patients with multiple myeloma . Blood 2008 ; 111 : 2521 – 2526 . 9 Attal M Harousseau JL Facon T . Intergroupe Francophone du Myelome: single versus double autologous stem cell transplantation for multiple myeloma . N

Full access

Jean-Luc Harousseau and Philippe Moreau

; 93 : 55 – 65 . 9. Attal M Harousseau JL Facon T . Single versus double autologous stem-cell transplantation for multiple myeloma . N Engl J Med 2003 ; 349 : 2495 – 2502 . 10. Sonneveld P van der Holt B Segeren CM . Intensive

Full access

Saurabh Rajguru and Brad S. Kahl

to patients aged 65 years or younger without significant comorbidities ( Table 1 ). Examples of intensive therapies include chemoimmunotherapy induction followed by autologous stem cell transplantation (ASCT) or the R-hyperCVAD (rituximab and

Full access

Shaji K. Kumar

asking whether patients with somewhat less risk can also benefit from early treatment. Newly Diagnosed Patients The key issue with newly diagnosed patients remains their eligibility for autologous stem cell transplant (ASCT). Transplant

Full access

Matthew Mei and George Somlo

than 80 years treated between 1973 and 2009. 1 Depth of response to therapy has long been associated with improved long-term outcomes. 2 Autologous stem cell transplantation (ASCT) was previously the only modality capable of inducing a very good

Full access

Edward A. Faber Jr. and Julie M. Vose

experienced an overall response rate of 93% and complete remission rate of 85% with a single myeloablative infusion of 131 I-tositumomab. After conventional autologous stem cell transplant, 5-year overall and progression-free survival rates were estimated to

Full access

Shira Dinner and Ranjana Advani

; 53 : 259 – 262 . 28. Younes A Sureda A Ben-Yehuda D . Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II study . J Clin Oncol 2012 ; 30 : 2197 – 2203